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Although chronic wounds have multifactorial aetiologies, they
share a common characteristic of compromise of the local vas-
culature leading to diminished oxygen tension.1 In pressure
ulcers (PU), the obstruction of capillary blood flow and lym-
phatics from the local shear pressure results in ischaemia. The
subsequent reperfusion causes hyperaemia and oedema, further
reducing the regional oxygen level.1 Similarly, in venous leg
ulcers (VLU), vascular permeability and increase in venous
hypertension generate local oedema. In diabetic foot ulcers
(DFU), hypoxia results from local pressure and high metabolic
stress on the wound bed. During the initial phase of healing for
all three wound types, the local and acute hypoxic climate
results in the release of numerous growth factors by endothelial
cells, fibroblasts and macrophages.1 One of those essential fac-
tors is the hypoxia inducible factor-1 (HIF-1). The regulation of
HIF-1 activity resides in its oxygen-dependent degradation, by
prolyl 4-hydroxylase (PHD) enzymes that require iron (Fe2+) as
a cofactor. Under hypoxic conditions, HIF-1a is stabilized
against PHD enzymatic degradation and moves to the nucleus,
where it dimerizes with HIF-1b and binds to a hypoxia response
element. For its transcriptional activity, HIF-1a also needs to
bind to the coactivators p300/cyclic adenosine monophosphate
response element binding protein (CREB) binding protein
(CBP).1 This results in the upregulation and the activation of
more than 60 HIF-1a target genes for tissue repair, cell growth
and proliferation, and important angiogenic factors such as vas-
cular endothelial growth factor (VEGF; Fig. 1).1 Although VEGF
induces angiogenesis, studies have shown that prolonged
hypoxia results in increased acidosis, decrease adenosine
triphosphate production and inhibition of neovascularization
that cannot be reversed by VEGF.1 This explains the need for a
therapeutic agent that would maintain the multitarget activity of
HIF-1a within the chronic wound environment (Fig. 1).
Another characteristic of chronic wounds is the local depo-
sition of free iron. In VLU, leakage of erythrocytes into the
interstitium and their degradation by macrophages leads to
the release of the iron bound to ferritin. In patients with dia-
betes, insulin resistance results in the increase in ferritin syn-
thesis and iron stores, which concurrently reduce the hepatic
extraction and metabolism of insulin, leading to hyperinsuli-
naemia.2 We speculate that the local tissue ischaemia with ves-
sel occlusion encountered in PU also leads to increased iron
deposition (Fig. 1).
Iron is a transition metal that has the ability to donate or
accept single electrons. This allows iron to neutralize free
radicals and thus to serve as a critical antioxidant defence.2 In
order to maintain the physiological redox status of the cells,
iron is sequestered bound with either proteins or cofactors.2 If
released from its bound form, free iron serves as a chemoat-
tractant for neutrophils and macrophages. The combination of
iron and hydrogen peroxide (from activated neutrophils) gen-
erates ferric ion (Fe3+) and reactive oxygen species (ROS), the
prolonged production of which results in a chronically
inflamed environment.1 A vicious cycle is created by the
reduction of ferric to ferrous ion (Fe2+), generating more
ROS, and the subsequent ROS enhancement of release of iron
from carriers (Fig. 1).1 Iron also induces an unrestrained
proinflammatory M1 macrophage phenotype, which con-
tributes to perpetual tissue damage and compromised tissue
regeneration as the cells fail to switch to the proreparative M2
phenotype.3 All of the above sustain the chronic inflammatory
state encountered in chronic wounds (Fig. 1).
We postulate that the topical application of deferoxamine
(DFO), which simultaneously acts as an iron chelator and
effective HIF-1a inducer and stabilizer, is a potential therapeu-
tic approach to improve healing of chronic wounds. DFO
could be topically administered to the impaired wound bed at
concentrations 100-fold lower than the therapeutic parenteral
infusion warranted in the treatment of thalassaemia or iron
poisoning, and with a better safety profile.
Preclinical studies have demonstrated that DFO topically
applied or injected improved wound healing in db/db mice,
with increased granulation tissue and neovascularization.1,4
DFO modulated the expression of several cytokines and
growth factors (including HIF-1a and VEGF).4 As a result,
DFO led to decreased inflammation, enhanced angiogenesis
and wound maturation. The authors proposed that DFO oint-
ment could potentially heal cutaneous wounds in patients with
diabetes.4 The addition of DFO to fibroblasts derived from
diabetic db/db mice cultured in hyperglycaemic and hypoxic
conditions resulted in increased expression of HIF-1a target
genes responsible for motility and angiogenesis.1 DFO
enhanced wound healing rates in the db/db mouse, even in
the presence of continuous hyperglycaemia.1
Human aortic endothelial cells cultured in high glucose and
hypoxia with DFO, resulted in a twofold elevation in HIF-1a
binding to p300 coactivator, approaching levels found in cells
cultivated in low glucose.1 DFO prevented the methylglyoxal
modification of p300, which has been shown to impact
negatively on the heterodimerization of the two HIF-1 sub-
units.1 Additionally, local injection of DFO into ischaemic
flaps of diabetic mice resulted in wound healing enhancement
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and prevention of flap necrosis by increasing HIF-1a
and VEGF expression, endothelial cell recruitment and
neovascularization.5
A very different approach by Duscher et al.6 demonstrated
transdermal drug delivery of DFO in reverse micelles that pen-
etrate the intact stratum corneum. This transdermal delivery
system improved PU healing and prevented ulcer formation in
diabetic mice. The authors suggested that this DFO delivery
system could prevent diabetic ulcers and improve wound heal-
ing in humans.6
Our (C.N.T.-F. and S.R.B.) translational experiments in radi-
ation-induced delayed bone healing have led us and others to
investigate DFO as a therapeutic option to optimize tissue
repair and regeneration.7 We used a murine mandibular
model of distraction osteogenesis (DO) and pathological frac-
ture in the setting of radiation. DO is a reconstructive tech-
nique that leads to endogenous bone regeneration after the
separation of two osteogenic fronts. In these models DFO
increased the vascular metrics compared with radiated
untreated controls.7 All of these aforementioned studies
demonstrate that DFO improves bony tissue repair, even in
the absence of hyperglycaemia-induced deficits. Although both
skin and bone are dynamic organs with different repair mech-
anisms, our findings corroborate those of others in the context
of delayed wound healing.
Clinical studies have correlated the severity of VLU with the
abundance of iron in the wound dermis.3,8 They also revealed
sizable amounts of iron in chronic wound exudates of VLU
compared with acute wound exudates.3,8
In vivo studies of patients with diabetes have shown that
hyperglycaemia impairs transferrin binding ability and aug-
ments ferritin synthesis,2 thus increasing the availability of
free iron and promoting ROS formation. In addition, hyper-
glycaemia interferes in a dose-dependent manner with HIF-1a
protein stabilization,1 resulting in low levels found in diabetic
wounds, with a concomitant decrease in angiogenesis con-
tributing to wound chronicity.
One of the earliest human studies linking DFO and gly-
caemic control in patients with diabetes was done in 1989.2
Following intravenous DFO administration, patients with dia-
betes with high serum ferritin no longer required hypogly-
caemic therapy.2 Thus, studying DFO therapy in clinical trials
may decrease diabetic complications, such as DFU.6 Most
other human clinical studies have focused on DFO’s protective
effect on the myocardium against reperfusion-induced free
radical formation in cardiac patients, or in the prevention of
iron-induced heart failure and arrhythmia in thalassaemia.2,6
In addition, DFO has been examined as a preventative measure
for intracerebral haemorrhage and therefore ischaemic stroke
as it counteracts iron-mediated neurotoxicity by decreasing
NO synthesis1
NO acon
Impaired endothelial 
reacvity
Ferrin
Ferrin
synthesis2
Insulin
ECM 
degradaon
MMP 
acvaon4
Bacterial 
bioburden1
HIF-1α ROS
Glucose
HIF-1α methyl-
glyoxal adducts1
Prolyl hydroxylase
LOCAL IRON 
deposion
Lipid and protein
peroxidaon1,7
CHRONIC INFLAMMATION
Cellular/ssue 
damage
Iron-induced 
M1 macrophages3
PU VLU DFU
Neutrophil 
dysfuncon1
Venous stasis: capillary permeability/RBC and protein 
extravasaon/RBC degradaon by macrophages
Type 2 diabetes: 
Insulin resistance2
Local ssue ischaemia:capillary 
blood flow, vessel/lymphac occlusion1,7
Growth factors 
(i.e., VEGF, HSP, SDF)1,5-7
Angiogenesis1,7
Cell molity1,7
Recruitment of        
endothelial precursors1,7
Fig 1. Schematic role of iron in the pathogenesis of chronic wound formation. RBC, red blood cells; MMP, matrix metalloprotease; ROS, reactive
oxygen species; HIF-1a, hypoxia-inducible factor-1; ECM, extracellular matrix; NO, nitric oxide; VEGF, vascular endothelial growth factor; HSP,
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cerebral oedema and neuronal death.6 However, to date there
are no human studies that have investigated the clinical appli-
cation of DFO for the treatment of any type of chronic
wound.
Given the hypoxia-driven environment of chronic wounds
and the toxic effect of local iron deposition, it is fair to postu-
late that a topical delivery of DFO could reverse those deleteri-
ous effects and make a significant contribution to wound
healing. Pharmacokinetic studies have shown that DFO is
highly hydrophilic and rapidly metabolized by plasma
enzymes,6,9 which leads to a short half-life of 12 min.6 There-
fore, there is decreased absorption by the gastrointestinal tract
and limited efficacy. Consequently, DFO has preferentially
been administered subcutaneously for the treatment of iron
overload.
DFO is usually well tolerated, and adverse reactions to DFO
have been insufficiently reported to quantify their frequency.
At high doses (exceeding 40 mg kg1 daily) subcutaneous
administration of DFO may produce pain and swelling at the
injection site, ocular, auditory, neurological disturbances and
renal insufficiency, with the latter shown to reverse upon dis-
continuation of DFO therapy.9 Hypotension, growth retarda-
tion in children and opportunistic infections, (in particular,
mucormycosis in patients on dialysis) have also been
reported.9 Severe pulmonary effects have been observed at
intravenous infusion doses of 10–20 mg kg1 hourly.9 As far
as the skin is concerned, a very rare generalized rash has been
described.6,9 Several randomized clinical trials on the use of
iron chelators for the treatment of thalassaemia have shown
that DFO has a good safety profile compared with other chela-
tors. There have not been any reactions reported from the
topical use of DFO.
Here we propose that DFO is administered topically at con-
centrations 100-fold lower than the therapeutic dosage used
parenterally in thalassaemia or iron poisoning, thus with a
better safety profile. A major potential barrier to penetration
of topically administered DFO is the stratum corneum, the
outermost layer of the skin. However, chronic wounds lack
the intact stratum corneum. In addition, numerous studies
have now documented that DFO uptake does not occur via
permeation across cellular membrane but rather via fluid-
phase endocytosis, leading to an exclusive intracellular location
within the endosome–lysosome complex.10 As the stratum
corneum is absent in chronic wounds and DFO absorption
occurs through an endosomal pathway, we anticipate easy
delivery of DFO and a direct absorption at the local wound
site, including weight-bearing areas such as plantar DFU.
We envision that DFO can be administered topically as a
solution, cream or medication delivery patch directly on the
wound bed. DFO would be readily available at the local
wound site as it would avoid the first pass by the liver.
The topical use of DFO as an iron chelator seems to have
multiple potential advantages. DFO can prevent iron release in
the tissue of patients with diabetes, or venous or PUs and
therefore indirectly inhibit the deleterious cascade of iron-
induced oxygen free radicals that overload the wound’s
antioxidant capacities and perpetuate the inflammatory damage
cycle. Furthermore, DFO-induced HIF-1a stabilization would
circumvent the chronic hypoxic milieu of PU, VLU and DFU,
and stimulate new vessels, potentiate cell motility and recruit-
ment of endothelial precursors, all of which are essential to
the healing phase of cutaneous wounds. Altogether, DFO has
the potential to provide a novel therapeutic tool to improve
healing in chronic wounds.
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